Logo featuring "BIOVECTRA" in purple text with a blue and yellow abstract design, and the phrase "A part of Agilent" below.
Facebook Linkedin

WHITE PAPER

Challenges and Opportunities in High-Potency Pharmaceuticals Manufacturing

The image is a white paper cover from C&EN titled "Challenges and Opportunities in High-Potency Pharmaceutical Manufacturing," featuring a download button and Biovectra logo.

Currently Accepting New Projects

As the pharmaceutical industry improves highly potent therapeutic targeting using small and large molecule approaches, the demand for HPAPIs continues to increase. With extensive HPAPI process development and production experience for small and large molecule APIs, BIOVECTRA is here to advance your project. Complex products that require specific handling, conjugation, or other specialized processing are areas where BIOVECTRA shines.

We offer pilot-to-commercial-scale HPAPI capabilities, providing full support throughout the product life cycle.

© BIOVECTRA 2024. All rights reserved

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications